Bid for inhaler company Bespak "some weeks away"
This article was originally published in Clinica
Executive Summary
Drug delivery equipment manufacturer Bespak, of Milton Keynes, UK, has told Clinica that it may be "some weeks" before there is any significant action regarding bids made for the company. Bespak revealed on April 8 that it had received a number of approaches, which may or may not lead to an offer for the entire share capital. In the ensuing days, no further progress was made, with a spokesman saying on April 17 that this was merely the early stages. The company would not confirm newspaper speculation that the private equity house HG Capital had made a bid.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.